Annals of Oncology Advance Access published online on December 15, 2005
Annals of Oncology, doi:10.1093/annonc/mdj109
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Istituto Oncologico Romagnolo, Forlì, Italy
* To whom correspondence should be addressed. Background: The aim of the present study was to evaluate the accuracy of two markers, maspin and mammaglobin B, singly or in combination, to detect breast cancer. To define better the potential and limits of the two markers for diagnostic purposes, blood positivity was analyzed in relation to clinical, pathological and biological tumor characteristics. Patients and methods: The markers were determined in peripheral blood (PB) samples from 27 healthy donors and 140 previously untreated patients using nested reverse transcriptase polymerase chain reaction (RT-PCR). Results: Positivity for maspin in blood samples was observed in 24% of patients with an 89% specificity. For mammaglobin B, positivity was observed in 7% of patients and never in healthy donors. The presence of maspin was correlated with cell proliferation of the primary tumor (P = 0.015), whereas mammaglobin B positivity correlated with pathological stage (P = 0.013). The presence of either marker was significantly related to nodal status. Conclusions: Our results indicate that the two markers in association could represent a potentially useful non-invasive tool to detect breast cancer. The validation of these markers as indicators of high risk of relapse is ongoing in a series of patients with an adequate follow-up.
Received July 29, 2005
Revised November 4, 2005
Accepted November 11, 2005
original article
RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients
L. Mercatali 1,
V. Valenti 1,
D. Calistri 1,
S. Calpona 1,
G. Rosti 2,
S. Folli 3,
M. Gaudio 4,
G. L. Frassineti 4,
D. Amadori 4,
and
E. Flamini 4 *
2 Department of Medical Oncology, S. Maria delle Croci Hospital, Ravenna, Italy
3 Department of Thoracic Surgery, Morgagni Pierantoni Hospital, Forlì, Italy
4 Division of Oncology and Diagnostics, Morgagni Pierantoni Hospital, Forlì, Italy
E. Flamini, E-mail: e.flamini{at}ausl.fo.it
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. I. Heath, D. W. Hillman, U. Vaishampayan, S. Sheng, F. Sarkar, F. Harper, M. Gaskins, H. C. Pitot, W. Tan, S. P. Ivy, et al. A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer Clin. Cancer Res., December 1, 2008; 14(23): 7940 - 7946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Kroemer, L. Galluzzi, and C. Brenner Mitochondrial Membrane Permeabilization in Cell Death Physiol Rev, January 1, 2007; 87(1): 99 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Khalkhali-Ellis Maspin: The New Frontier Clin. Cancer Res., December 15, 2006; 12(24): 7279 - 7283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lacroix Significance, detection and markers of disseminated breast cancer cells Endocr. Relat. Cancer, December 1, 2006; 13(4): 1033 - 1067. [Abstract] [Full Text] [PDF]
|
|